Lipigon Pharmaceuticals AB (LPGO) — Capital Reinvestment Ratio

Latest as of March 2020: 0.39x

Lipigon Pharmaceuticals AB (LPGO) has a Capital Reinvestment Ratio of 0.39x as of March 2020, meaning it reinvests 0% of its operating cash flow (Skr309.00K) in capital expenditures (Skr119.00K). See Lipigon Pharmaceuticals AB free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.

Capital Reinvestment Ratio

0.39x

Capex / Operating Cash Flow

Operating Cash Flow

Skr309.00K

SEK

Capital Expenditures

Skr119.00K

SEK

Data as of

Mar 2020

Most recent filing

Annual Capital Reinvestment Ratio for Lipigon Pharmaceuticals AB (None–None)

Year-by-year Capital Reinvestment Ratio for Lipigon Pharmaceuticals AB from None to None. For live market cap and broader valuation context, see LPGO company net worth.

Year	Reinvestment Ratio	Operating CF (SEK)	Capital Expenditures	YoY Change

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow